Patents by Inventor Eugene L. Saklad

Eugene L. Saklad has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 4337240
    Abstract: Small sized material (less than 0.2 .mu.m, preferably less than 0.1 .mu.m) comprising a complex of (1) denatured albumin, particularly human serum albumin and (2) a metal reducing agent, particularly a stannous reducing agent, preferably formed in the presence of a stabilizing ligand, which complex, when labelled with technetium-99m provides an excellent agent for imaging or otherwise evaluating reticuloendothelial systems (RES) and/or components thereof, particularly the bone marrow, liver and/or lymphatic system; methods of making and using the same; a complex (physical or chemical) of technetium-99m with such materials and methods of using such latter complex.
    Type: Grant
    Filed: March 7, 1979
    Date of Patent: June 29, 1982
    Assignee: New England Nuclear Corporation
    Inventor: Eugene L. Saklad
  • Patent number: 4226846
    Abstract: Microaggregates of a complex of (1) albumin, particularly human serum albumin and (2) a metal reducing agent, particularly a stannous reducing agent, preferably formed in the presence of a stabilizing ligand, which complex, when labelled with technetium-99m provides an excellent agent for imaging reticuloendothelial systems (RES), particularly the liver, spleen, and bone marrow; methods of making and using the same; a complex (physical or chemical) of technetium-99m with such microaggregates and methods of using such latter complex.
    Type: Grant
    Filed: April 20, 1978
    Date of Patent: October 7, 1980
    Assignee: New England Nuclear Corporation
    Inventor: Eugene L. Saklad
  • Patent number: 4094965
    Abstract: Diagnostic compositions comprising serum albumin which has been treated to remove fats and fatty acids with possible changes in molecular conformation, a reducing agent, preferably a stannous reducing agent, and a radionuclide, preferably technetium-99m, are highly useful in study and diagnosis of morphology and functions of animal tissues and organs, particularly in studying cardiovascular dynamics, placental imaging, cisternography, in determining blood and plasma volumes, in metabolism and turnover studies, in radioscintigraphic diagnosis of the lung and reticuloendothelial systems, e.g. pulmonary emboli, bronchogenic carcinoma, pneumonitis, emphysema, tuberculosis, pathology of liver and/or spleen manifest by changes in size or shape or pathology of adjacent structures or displacement of these organs, and other disorders.For pulmonary and reticuloendothelial applications, the albumin is converted to particulate forms by denaturation under conditions which form aggregates of appropriate size.
    Type: Grant
    Filed: April 1, 1977
    Date of Patent: June 13, 1978
    Assignee: New England Nuclear Corporation
    Inventors: Warren W. Layne, Eugene L. Saklad